Brief: Neurogene Inc - Participant In Neurogene's Phase 1/2 Trial For Rett Syndrome Dies
21/11/2024 21:15
Nov 21 (Reuters) - Neurogene Inc NGNE.O :
* NEUROGENE INC - PARTICIPANT IN NEUROGENE'S PHASE 1/2 TRIAL
FOR
RETT SYNDROME DIES
* NEUROGENE INC - FDA ALLOWS NEUROGENE TO PROCEED WITH PHASE
1/2
TRIAL USING 1E15 VG DOSE
Source text: t.ly/aIzVh
Further company coverage: NGNE.O
Recent news on Neurogene
See all newsBrief: Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Neurogene Inc reports results for the quarter ended June 30 - Earnings Summary
Neurogene Q2 adjusted loss per share misses estimates on employee costs
Neurogene Inc expected to post a loss of $1.42 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Kroger, Meta, Sable